The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as
a digital meeting through Microsoft Teams. All proposals on the agenda were
adopted in accordance with the board of directors' proposals and the proposals
from the nomination committee.
The minutes of the annual general meeting are attached hereto and are also
available on the company's website
www.oncoinvent.com/investors/general-meetings.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alphaemitting radionuclides to deliver powerful radiation directly to
cancer cells. The Company's lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.
This information is subject to disclosure under the Norwegian Securities Trading
Act section 5-12 and the requirements of Oslo Børs' Continuing Obligations.